Effect of desogestrel 75 µg on headache frequency and intensity in women with migraine: a prospective controlled trial. (4th May 2019)

• Record Type: Journal Article
• Authors: Merki-Feld, Gabriele S.; Imthurn, Bruno; Gantenbein, Andreas R.; Sandor, Peter
• Is Part Of: European journal of contraception & reproductive health care. Volume 24:Number 3(2019)
• Page Start: 175
• Page End: 181
• Publication Date: 2019-05-04
• Subjects: Combined oral contraceptive pill -- contraception -- desogestrel -- estrogen-withdrawal headache -- migraine prevention -- migraine without aura -- triptans; Contraception -- Periodicals; Reproductive health -- Periodicals; Generative organs, Female -- Periodicals; Contraception -- Periodicals; Reproductive Medicine -- Periodicals; 613.9
• DOI: 10.1080/13625187.2019.1605504
• Languages: English
• ISSNs: 1362-5187

Abstract

Abstract: Objective: In contrast with combined hormonal contraception, progestin-only contraception is not associated with an increase in venous thromboembolism or stroke. Women with migraine are at increased risk of ischaemic stroke. Several studies have reported a reduction in migraine frequency and intensity with desogestrel 75 µg, a progestin-only pill. At present the quality of data is limited by retrospective study designs, lack of control groups and small sample sizes. We present the first prospective nonrandomised controlled trial. Methods: A total of 150 women with migraine visiting our clinic for contraceptive counselling were screened. The intervention group comprised women who opted for contraception with desogestrel ( n = 98); the control group comprised women who continued their usual contraceptive ( n = 36). Participants completed daily diaries for 90 days before the intervention and 180 days after the intervention. Results: In the intervention group, we found improvements in migraine frequency ( p < .001), migraine intensity ( p < .001) and the number of triptans used ( p < .001). These improvements were already significant after 90 days of desogestrel use ( p < .001). Disability scores also decreased significantly. No improvement was seen in the nonintervention group. Conclusion: These data demonstrate for the first time in a prospective controlled setting that daily use of the progestin desogestrel is associated with a decrease in migraine frequency, migraine intensity and pain medication use in women with migraine, with and without aura, who had previously been experiencing at least three days of migraine per month. Trial registration: The study is registered in the University of Zürich database (www.research-projects.uzh.ch/unizh.htm ).